IBOV 177,418.78 ▲ 1.00% IPSA 11,315.26 ▼ 1.14% IPC MEX 65,048.39 ▼ 0.67% MERVAL 3,033,848 ▲ 1.83% COLCAP 2,425.08 ▼ 1.33% BVL PERÚ 59,928.30 ▼ 0.80% USD/BRL5.18▼ 0.16% USD/MXN16.99▼ 0.28% USD/CLP933.85▲ 0.25% USD/COP3,219▲ 0.60% USD/PEN3.36▲ 0.39% USD/ARS1,509▼ 0.28% USD/UYU40.29▲ 0.05% USD/PYG5,892▼ 0.13% USD/BOB11.84▲ 0.51% USD/DOP58.64▲ 0.05% USD/CRC446.47▼ 0.04% USD/GTQ7.62▼ 0.02% USD/HNL26.84— 0.00% USD/NIO36.62— 0.00% USD/VES793.00▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.69▼ 0.37% EUR/BRL6.02▼ 0.09% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 177,418.78 ▲ 1.00% IPSA 11,315.26 ▼ 1.14% IPC MEX 65,048.39 ▼ 0.67% MERVAL 3,033,848 ▲ 1.83% COLCAP 2,425.08 ▼ 1.33% BVL PERÚ 59,928.30 ▼ 0.80% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Monday, August 31, 2026

Latin America Argentina

Milei’s Anti-Corruption Credibility Tested as Drug Contract Scandal Engulfs His Inner Circle

By · August 26, 2025 · 2 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

Argentina’s president Javier Milei entered the campaign season defending his sister Karina after leaked recordings suggested bribery in state medicine contracts.

The case, now under court investigation, threatens his anti-corruption message and exposes the business stakes in Argentina’s vast pharmaceutical supply chain.

Federal Judge Sebastián Casanello ordered raids on the National Disability Agency (ANDIS) and private homes. He froze assets of former agency head Diego Spagnuolo, procurement officials, and executives of Suizo Argentina, a major medical supplier.

found executive Emmanuel Kovalivker with $266,000 in envelopes, while his brother Jonathan surrendered his phone after initially avoiding investigators.

The recordings attributed to Spagnuolo describe an alleged eight percent surcharge demanded from drug companies in exchange for state contracts. They mention Karina Milei and Eduardo “Lule” Menem, a presidential organizer. Both deny involvement.

Milei’s Anti-Corruption Credibility Tested as Drug Contract Scandal Engulfs His Inner Circle
Milei’s Anti-Corruption Credibility Tested as Drug Contract Scandal Engulfs His Inner Circle. (Photo Internet reproduction)
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

Procurement data confirm Suizo Argentina’s government contracts rose sharply, from about 3.9 billion pesos in 2024 to roughly 108 billion pesos in 2025, after it secured a logistics role for medicine and vaccine deliveries.

That surge in state business put the company at the center of the scandal. The Milei government dismissed the accusations as a Kirchnerist ploy to destabilize ahead of elections.

At a rally in Junín, the president praised his sister and accused opponents of “sowing chaos.” A remark about “stealing their steals” drew widespread criticism online.

The case cuts deeper because ANDIS finances medicine and treatments for Argentines with disabilities and non-contributory pensions. Any diversion of funds undermines care for those who depend on public support.

The timing raises the stakes. Buenos Aires province, home to nearly four in ten Argentines, votes on September 7. National midterms follow October 26. The outcome will decide whether Milei can advance his economic agenda, even as his closest allies face legal scrutiny.

For international readers, the story matters because it shows how fragile anti-corruption platforms can become when campaign allies and family members face direct accusations.

It also highlights how lucrative public health contracts can fuel political battles in emerging markets, where billions in taxpayer funds depend on transparent oversight.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.